Abril-Rodriguez G, Ribas A (2017) SnapShot: immune checkpoint inhibitors. Cancer Cell 31(6):848-848.e1

Article  CAS  PubMed  Google Scholar 

Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S et al (2015) Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373(19):1803–1813

Article  CAS  PubMed  PubMed Central  Google Scholar 

Eggermont AMM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H et al (2016) Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med 375(19):1845–1855

Article  CAS  PubMed  PubMed Central  Google Scholar 

Barroso-Sousa R, Barry WT, Garrido-Castro AC, Hodi FS, Min L, Krop IE et al (2018) Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol 4(2):173

Article  PubMed  Google Scholar 

Cortazar FB, Kibbelaar ZA, Glezerman IG, Abudayyeh A, Mamlouk O, Motwani SS et al (2020) Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: a multicenter study. J Am Soc Nephrol févr 31(2):435–446

Article  CAS  Google Scholar 

Kitchlu A, Jhaveri KD, Wadhwani S, Deshpande P, Harel Z, Kishibe T et al (2021) A systematic review of immune checkpoint inhibitor-associated glomerular disease. Kidney Int Rep 6(1):66–77

Article  PubMed  Google Scholar 

Oaknin A, Pothuri B, Gilbert L, Sabatier R, Brown J, Ghamande S et al (2023) Safety, efficacy, and biomarker analyses of Dostarlimab in patients with endometrial cancer: interim results of the phase I GARNET study. Clin Cancer Res 29(22):4564–4574

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cortazar FB, Marrone KA, Troxell ML, Ralto KM, Hoenig MP, Brahmer JR et al (2016) Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int sept 90(3):638–647

Article  CAS  Google Scholar 

Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM et al (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 36(17):1714–1768

Article  CAS  PubMed  Google Scholar 

Palamaris K, Alexandris D, Stylianou K, Giatras I, Stofas A, Kaitatzoglou C et al (2022) Immune Checkpoint Inhibitors’ Associated Renal Toxicity: a series of 12 cases. J Clin Med 11(16):4786

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang Z, Xu H, Gou S, Wu H, Hu Z (2023) Pembrolizumab induced-C3 glomerulonephritis and RBC cast nephropathy: a case report. BMC Nephrol 24(1):145

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mirza MR, Chase DM, Slomovitz BM, de Pont Christensen R, Novák Z, Black D et al (2023) Dostarlimab for primary advanced or recurrent endometrial cancer. N Engl J Med 388(23):2145–2158

Article  CAS  PubMed  Google Scholar 

Oaknin A, Gilbert L, Tinker AV, Brown J, Mathews C, Press J et al (2022) Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I, single-arm study. J Immunother Cancer janv 10(1):e003777

Article  Google Scholar